Top Markets
#1 Celer Network Celer Network +49.10%
#2 Gravity Gravity +24.44%
#3 Galxe Galxe +23.88%
#4 ICON ICON +13.39%
#5 MemeCore MemeCore +13.25%
#6 Cartesi Cartesi +12.87%
#7 Zilliqa Zilliqa +10.95%
#8 Genius Genius +10.65%
#9 Ontology Gas Ontology Gas +9.33%
#10 CyberDEX CyberDEX +7.13%
Coin of the day
Celer Network Celer Network
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Classifica tra le azioni #40225
Fusion Antibodies plc operates as a contract research organization (CRO),... Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
Prezzo delle azioni
$0.1559364
Ultima sincronizzazione: 2026-09-18
Capitalizzazione di mercato
$195.17K
Variazione (1 giorno)
6.60%
Variazione (1 anno)
-30.91%
Paese
GB
Scambia Fusion Antibodies plc (FAB)

Categoria

Healthcare
Ricavi di Fusion Antibodies plc (FAB)
Ricavi nel Sep 2025 TTM: $2.15M
Secondo gli ultimi rapporti finanziari di Fusion Antibodies plc, i ricavi attuali dell'azienda (TTM) sono pari a $2.15M. Nel 2024, l'azienda ha registrato ricavi di $1.43M una diminuzione rispetto a i ricavi dell'anno 2023, che erano pari a $3.58M. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Fusion Antibodies plc da 2013 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
2026 (TTM) $2.15M -15.49%
2025 $2.54M 77.00%
2024 $1.43M -59.95%
2023 $3.58M -43.24%
2022 $6.31M 9.89%
2021 $5.74M 18.80%
2020 $4.83M 70.09%
2019 $2.84M -24.66%
2018 $3.77M 57.07%
2017 $2.40M 12.81%
2016 $2.13M 57.86%
2015 $1.35M 11.90%
2014 $1.20M 95.78%
2013 $615.46K 0.00%
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 588,305.51%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 280,545.95%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 103,744.77%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 733,726.73%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH